Hi, help us enhance your experience
Hi, help us enhance your experience
Hi, help us enhance your experience
922 Views
Dr PK Hazra, Kolkata 04 January 2018
Approximately 40,000-50,000 CA/HF patients receive international device therapies like pacemakers, ICD, CRT and/or RFA.2 In Asia Pacific region, patients receive lower-than-recommended levels of pharmacological treatment.3 The cornerstone of contemporary pharmacological therapy targets the over activated renin-angiotensin-aldosterone and sympathetic autonomous systems.4 In 2016, the focused pharmacologic update on the current Heart Failure Guidelines introduced the use of two newly approved drug regimens: Valsartan/sacubitril and ivabradine. These novel compounds were reported to exert additional mortality and morbidity benefits in heart failure subpopulations with reduced ejection fraction.4
References
{{Article_Title}}
{{Article_Author}}
{{Article_Title}}
{{Article_Author}}